Intracoronary streptokinase in clinical practice.
The candidacy for streptokinase (SK) infusion was studied in 95 patients displaying ECG evidence of acute or impending infarction who were catheterized within 5 hours of the onset of chest pain. Intracoronary SK was administered to 84 patients in whom occlusions of the infarct-related vessel were identified, with early recanalization having been achieved in 74 (88%). Because of completeness of studies, a data base of 72 patients was employed for further analysis. Recanalization was sustained at follow-up in 45 of 55 patients (82%). Spontaneous thrombolysis was demonstrated at follow-up in five patients (8%) initially resistant to SK, and rethrombosis occurred in 10 patients (18%). Preservation of R waves relative to Q wave depth was limited to patients with less than 90% residual stenosis. Eight of nine patients with continuing thrombolysis and patients with recanalized occlusions of the left anterior descending coronary artery displayed more impressive increases in mean (+/- SEM) ejection fraction (47% +/- 4% to 53% +/- 5% [p less than 0.05], and 47% +/- 3% to 52% +/- 5, respectively). The ejection fraction also increased significantly in 15 patients with pre-SK values of less than 50% (41% +/- 2% to 48% +/- 3%; p less than 0.05). Ventricular function deteriorated in SK failures. Reperfusion arrhythmias occurred in 28 of 62 recanalized patients (45%). Minor bleeding tendencies were displayed in 18 of 72 patients (25%). Major hemorrhages, one of which may have been fatal, occurred in four patients (5.6%). Of 84 patients, four (4.7%) died, two of whom were in cardiogenic shock when first seen. In contrast, there were 11 deaths (11.8%) in a consecutive simultaneously enrolled series of 93 control patients with similar entry criteria (p less than 0.05). Two additional SK-treated patients died, 16 and 30 days after treatment, both more than a week after surgical revascularization. It is concluded that SK recanalization is a promising new therapy that may decrease mortality and preserve myocardial function in certain circumstances. Its efficacy in a setting closer to the mainstream of cardiologic practice extends the favorable experience issuing from earlier clinical investigations.
D000328:Adult; D000368:Aged; D001157:Arterial Occlusive Diseases / Q000473:pathology; D003251:Constriction, Pathologic / Q000473:pathology; D003326:Coronary Circulation; D003402:Creatine Kinase / Q000097:blood; D004562:Electrocardiography; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007269:Injections, Intra-Arterial; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000401:mortality; D010043:Outcome and Process Assessment, Health Care; D005082:Physical Exertion; D011877:Radionuclide Imaging; D013300:Streptokinase / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D013318:Stroke Volume
D003402:Creatine Kinase; D013300:Streptokinase